Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Sutro Biopharma

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2003-01-01

Employees: 324

Market Cap: $392.6M

Website: http://www.sutrobio.com

Introduction: Sutro Biopharma, Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.

Clinical Trials

Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age with Relapsed/Refractory CBFA2T3::GLIS2 AML

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia (AML)

Interventions: Drug: Luveltamab tazevibulin

First Posted Date: 2024-11-07

Last Posted Date: 2024-12-17

Lead Sponsor: Sutro Biopharma, Inc.

Target Recruit Count: 24

Registration Number: NCT06679582

Locations: 🇺🇸
Childrens Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Childrens National Hospital, Washington, District of Columbia, United States
🇺🇸
Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, United States

and more 1 locations

Study to Investigate Luveltamab Tazevibulin in Adults with Advanced or Metastatic Non-small Cell Lung Cancer

Phase 2

Recruiting

Conditions: Lung Cancer
Lung Cancer Non-Small Cell Stage IIIB
Lung Cancer Metastatic
Lung Cancer, Non-small Cell
Lung Cancer, Nonsmall Cell
Lung Cancer Non-small Cell Stage IV

Interventions: Drug: Luveltamab tazevibulin

First Posted Date: 2024-08-15

Last Posted Date: 2024-11-07

Lead Sponsor: Sutro Biopharma, Inc.

Target Recruit Count: 43

Registration Number: NCT06555263

Locations: 🇺🇸
Tampa General Hospital, Tampa, Florida, United States
🇺🇸
HealthPartners Cancer Research Center, St. Paul, Minnesota, United States
🇺🇸
Florida Cancer Specialists, Lake Mary, Florida, United States

and more 1 locations

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Phase 2

Recruiting

Conditions: Ovarian Cancer
Epithelial Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer
Platinum-resistant Ovarian Cancer

Interventions: Drug: Gemcitabine
Drug: Luveltamab tazevibulin
Drug: Pegfilgrastim
Drug: Paclitaxel
Drug: Pegylated liposomal doxorubicin
Drug: Topotecan

First Posted Date: 2023-05-23

Last Posted Date: 2024-08-29

Lead Sponsor: Sutro Biopharma, Inc.

Target Recruit Count: 600

Registration Number: NCT05870748

Locations: 🇺🇸
Arizona Oncology Associates, PC-Hope, Tucson, Arizona, United States
🇺🇸
Sutter Health, Daly City, California, United States
🇺🇸
MedStar Washington Hospital Center, Washington, District of Columbia, United States

and more 36 locations

A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer

Phase 1

Recruiting

Conditions: Ovarian Cancer
Ovarian Carcinoma
Ovary Cancer
Fallopian Tube Cancer
Primary Peritoneal Carcinoma

Interventions: Drug: STRO-002
Drug: Bevacizumab

First Posted Date: 2022-01-20

Last Posted Date: 2024-11-07

Lead Sponsor: Sutro Biopharma, Inc.

Target Recruit Count: 58

Registration Number: NCT05200364

Locations: 🇺🇸
University of South Florida,, Tampa, Florida, United States
🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

and more 3 locations

Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers

Phase 1

Completed

Conditions: Endometrioid Adenocarcinoma
Ovarian Cancer
Ovarian Carcinoma
Primary Peritoneal Carcinoma
Ovary Cancer
Endometrial Cancer
Fallopian Tube Cancer

Interventions: Drug: STRO-002

First Posted Date: 2018-11-20

Last Posted Date: 2025-01-16

Lead Sponsor: Sutro Biopharma, Inc.

Target Recruit Count: 136

Registration Number: NCT03748186

Locations: 🇺🇸
Arizona Oncology - Tucson, Tucson, Arizona, United States
🇺🇸
UCLA Jonsson Comprehensive Cancer Center Clinical Research Unit, Los Angeles, California, United States
🇺🇸
Sutter Health- Palo Alto Medical Foundation, San Francisco, California, United States

and more 24 locations

Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

Phase 1

Completed

Conditions: Indolent Lymphoma
Multiple Myeloma
Diffuse Large B Cell Lymphoma
Non Hodgkin Lymphoma
Follicular Lymphoma
B Cells--Tumors
B-cell Lymphoma
Mantle Cell Lymphoma

Interventions: Drug: STRO-001

First Posted Date: 2018-02-07

Last Posted Date: 2024-06-11

Lead Sponsor: Sutro Biopharma, Inc.

Target Recruit Count: 70

Registration Number: NCT03424603

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Arizona Oncology Associates, PC--HOPE Division, Tucson, Arizona, United States
🇺🇸
City of Hope Medical Center, Duarte, California, United States

and more 19 locations

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy